

Corporate Presentation

Creso Pharma Acquisition
of Psychedelic Company
Halucenex Life Sciences Inc.

March 2021





Bridging the gap between nature and pharmaceutical

Halucenex Life Sciences Inc. is a Canadian based life sciences development company focused on researching, developing and licensing novel psychedelic compounds for the global pharmaceutical and nutraceutical markets.

Creso Pharma acquisition to supercharge growth



Creso to implement broad pharmaceutical knowledge

Both parties to benefit from the Creso team's exceptional track record of developing and bringing pharmaceutical products to market, with over 8 nutraceutical, cosmetic and therapeutic products launched to date



Potential for product innovation with combination opportunities

Halucenex and Creso to progress potential combinations with cannabinoids and other psychedelic compounds to broaden current product suite and delivery methods



Established global footprint and market opportunities

Halucenex to directly benefit from Creso's international operations, distribution network and customer base, with existing products and distribution agreements in markets across the Asia Pacific, Americas, Europe, and African continents



Access to a world-class cannabis cultivation facility with the ability to operate as a psychedelic psilocybin mushroom cultivator

Via wholly owned subsidiary Mernova Medicinal Inc., Halucenex will have access to a cutting-edge cannabis cultivation facility fitted with infrastructure which can readily be adapted for the cultivation of psychedelic psilocybin mushrooms

The acquisition of Halucenex will allow Creso to perform high quality psychedelic product research once licensed. CPH's facilities can be utilised to develop, cultivate, extract, process and export Psilocybin.



Halucenex is positioned to lead innovation in the psychedelics assisted medicines space

Upon receipt of licence, will be fully licensed with access to a medical facility optimally located and fit for conducting clinical trials

Controlled Drugs and Substances Dealer's Licence allows for research and development of psilocybin

Halucenex operates a 6,000 sq. ft. medical clinic facility in Nova Scotia, Canada, which contains 18 treatment rooms and is next to an Emergency hospital

Aiming to be one of a small number of vertically integrated Canadian providers of Psychedelic-Assisted Psychotherapy

Controlled Substances License and CTA Permit under application – once granted, Halucenex will be one of a small number companies operating entirely out of Canada

Supply secured from Canada's only pharmaceutical-grade psilocybin producer

Synthetic psilocybin supply secured from Psygen, guaranteeing supply and availability for defined clinical trial program

Fast track to early revenue generation

Halucenex has strategic affiliations with Veterans Affairs Canada and Veteran Support Groups via Adviser David Fraser – provides a fast route to a market with major demand. Halucenex to target treatment of Treatment Resistant Depression and Anxiety

Large and emerging market opportunity

The economic burden of mental illness in Canada is estimated at C\$51Bn, while COVID-19 has worsened the global mental health crisis. More than 340m people suffer from mental illness globally¹ – current available treatments for mental illness have limited effectiveness and many side effects



1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018.

What is Psychedelic-Assisted Psychotherapy?

What are psychedelics?

Psychedelics (also known as hallucinogens) are a class of psychoactive substances that produce changes in perception, mood and cognitive processes.^[1]

Psychedelics affect all the senses, altering a person's thinking, sense of time and emotions. They can also cause a person to hallucinate – seeing or hearing things that do not exist or are distorted.

There are many different kinds of psychedelics. Some occur naturally, in trees, vines, seeds, fungi and leaves. Others are synthetic and made in laboratories.

Studies have shown that psychedelics may be able to treat disorders such as depression^[2], anxiety^[2], substance addiction^[3], and obsessive compulsive disorder^[4].

1. Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews*, 68(2), 264-355. <https://doi.org/10.1124/pr.115.011478>

2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/>


3. https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

4. Moreno, F.A., Wiegand, C.B., Keolani Taitano, E., Delgado, P.L. 2005. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *Journal of Clinical Psychiatry*, 67(11), 1735-1740.



Halucenex's three-tiered strategy

A defined, three-tiered strategy to become a vertically integrated provider of psilocybin and psychedelic assisted psychotherapy to revolutionise the treatment of mental illnesses



Becoming A Clinical Drug Pipeline Provider of Psychedelic-Assisted Psychotherapy

Halucenex is aiming to complete a Phase 2 clinical trial testing the effects of psilocybin on Treatment Resistant Depression in Veterans suffering Post Traumatic Stress Disorder.

Accelerated path to commercialization via affiliation with Veterans Affairs Canada.

Halucenex will move to Phase 3 clinical trials with a larger, broader client base once post efficacy is demonstrated.

Research Into Interactions Between Synthetic Psilocybin & Natural Psychedelic Psilocybin Mushrooms

Under the permitted terms of its Controlled Substances License, Halucenex will cultivate natural Natural Psychedelic Psilocybin mushrooms and undertake extraction of a number of psychedelic derivatives. Halucenex will perform further testing of potential entourage effects between natural and synthetic psilocybin to develop further IP.

The Development of a Proprietary Synthetic Psilocybin Formulation

Under its Controlled Substances License and in collaboration with non-profit organization Mitacs and Acadia University, Halucenex is developing core IP around a proprietary formulation of synthetic psilocybin to de-risk supply, increase yields for future micro and macro dosing formulations, and to open the manufacturing vertical.

The market

Halucenex is targeting two markets with a large unmet need:



1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047000/>

Psilocybin: A psychedelic used in Psychedelic-Assisted Psychotherapy

What is Psilocybin?

The active chemical found in Psychedelic Psilocybin mushrooms



Psilocybin and psilocin are psychedelic drugs found in fresh Psychedelic Psilocybin mushrooms that grow across the Americas, and have been used for spiritual and religious purposes in a number of cultures for centuries.

Both psilocybin and psilocin can also be produced synthetically in a lab.

New research on psilocybin suggests that it has the potential to 'break an individual's habitual patterns of thought', bringing about a change in their outlook.

How is psilocybin used in Psychedelic-Assisted Psychotherapy?

About macro and micro dosing

Halucenex is working to advance the scientific understanding of microdosing for clinical purposes.

Psychedelic-assisted psychotherapy with microdoses refers to therapeutic practices that involve the ingestion of a microdose of a psychedelic drug. The aim of a microdose is to dose a small enough quantity to trigger the drug's therapeutic benefits without the potentially disruptive effects seen at higher doses ("macrodose"), such as hallucinations.

Synthetic psilocybin is preferred in a clinical setting

Natural psilocybin is less compatible in clinical settings due to inconsistency of potency and therefore dosage.

Health Canada approves clinical trials only if companies have access to synthetic psilocybin to ensure consistency of dosage and purity in formulations.



Halucenex's clinical treatment facility is optimally located

Halucenex operates a 6,000 square foot medical facility, strategically located on a 160,000 sq ft lot adjacent to The Hants Community Hospital in Windsor, Nova Scotia, and which specialises in the treatment of mental health conditions.

The facility includes a Controlled Substances Laboratory and 18 treatment rooms dedicated to performing psychedelic-assisted psychotherapy and clinical research in micro and macro dosing.



Hants Community Hospital



Halucenex Medical Facility



Treatment rooms designed to appear as comfortable as living rooms

Halucenex will be fully licensed to commence clinical trials



Controlled Drugs and Substances Dealer's Licence Application Awarded

Expected Award Date: By end of March 2021



Clinical Trial Application to be Submitted

Controlled Drugs and Substances License (Dealer's License): permits the possession and research and development of psilocybin, LSD and MDMA ^[1]

- When awarded by Office of Controlled Substances (OCS), Halucenex will be only one of two public Canadian companies to hold a Dealer's License (the other is Numinus (TSXV:NUMI))
- Halucenex will have a 10g allowable possession of psilocybin under the Dealer's License
- Once awarded the Dealer's License, Halucenex will have complete control over the R&D process without having to rely on universities, many of which have been disrupted due to COVID-19
- Competitors are dependent on partnerships with Universities to complete R&D on psychedelics

Clinical Trial Application (CTA) expected to be submitted to Health Canada by end April 2021

1. Halucenex intends to apply and receive a proposed amendment to the Dealer's License to provide the authority to produce, assemble, sell, transport, import and export psychedelics.

Halucenex has access to one of the largest supplies of synthetic psilocybin in Canada

Psilocybin remains a Schedule I drug in most countries, however demand for research and clinical use is at all time highs

Psygen

Supply of pharmaceutical-grade synthetic psilocybin has been restricted due to:

- High barriers to entry prevent new players from supplying the market
- Lack of expertise in psychedelic medicinal chemistry
- Long lead time to obtain a license to produce restricted drugs
- High cost of building GMP compliant manufacturing facilities

Agreement Signed with Psygen Industries Ltd

- Guaranteeing supply of 11.6 grams of high quality, GMP grade synthetic psilocybin, an amount sufficient to take Halucenex up to conclusion of its Phase 3 Trial with immediate availability for Phase 2 Trials
- Psygen is the only pharmaceutical-grade psilocybin producer in Canada
- Halucenex is one of only 11 companies to secure supply from Psygen

Halucenex's three tiered business strategy



Tier



In collaboration with Mitacs and Acadia University, Halucenex is developing its own proprietary synthetic psilocybin formulation to secure access to in-house supply

January 2021 – June 2021



Project synthesis

Dr. Amitabh Jha, (Acadia University, Chemistry) is currently collaborating with Halucenex on Multi-Gram Scale Synthesis, Purification and Formulation of Psilocybin.

The overarching objective of this research is to synthesize psilocybin in multi-gram scale and subsequently develop appropriate formulations for preclinical experiments.

Developing IP around a formulation of synthetic psilocybin will allow Halucenex to replace existing third-party supply agreements and enter the market as a supplier to distributors and practitioners.

This constitutes an ambitious undertaking in the direction of drug-development.

Research-objectives:

- Multi-gram scale synthesis of psilocybin
- Purification and characterization of the synthesized target molecule
- Standardization of new and short synthetic route to psilocybin
- Preparing various formulations of psilocybin for the purpose of achieving the goal of controlled slow release administration of psilocybin
 - Carboxymethyl cellulose formulation
 - Chitosan formulation
 - Agarose formulation

Halucenex's three tiered business strategy



Tier



In collaboration with Acadia University, Halucenex will:

- Perform phytochemical screening of selected Psilocybe mushroom species aimed to isolate and identify hallucinogenic alkaloids
- Perform behavioural and neurophysiological bioassays in order to assess the psychoactive effects of psilocybin alone and in combination with other psilocybin-derivatives.

February 2021 – April 2022



This project will gather pivotal information to develop and test a novel commercial line of organic and synthetic psychoactive drugs based on hallucinogenic mushrooms. Given the promising anxiolytic and anti-depressive properties of psilocybin and psilocybin-derivative compounds, this research has broad and far-reaching clinical potential.

Research Objectives:

Chemistry:

- Collection of crude extracts through extraction procedures;
- Characterization of mushroom extracts specifically looking at the isolation and identification of indole-alkaloids;
- Quantification of indole-alkaloids;
- Preparation of selected compounds to be tested by mixing psilocybin with individual indole-alkaloids in a binary and tertiary mixture;
- optimization of the extraction protocol;

Behaviour and neurophysiology – testing behavioural and neurophysiological studies effects of:

- crude extracts;
- psilocybin alone;
- psilocybin in combination with binary and tertiary mixtures of isolated indole-alkaloids

Halucenex's three tiered business strategy



Tier



In partnership with True North and Everest Clinical Research, Halucenex will conduct a Phase 2 clinical trial to demonstrate efficacy of psilocybin in the treatment of Treatment Resistant Depression in Canadian veterans

June 2021 – March 2022

Phase 2 clinical trial

- The Phase 2 trial is to begin subject to Halucenex being awarded the clinical trial authorization permit (CTA Permit) by Health Canada
- Patients will be treated with a micro dose of 10mg of psilocybin and a follow up macro dose of 25mg
- Number of subjects: 18



TRUE NORTH
CLINICAL RESEARCH



Clinical trial timeline – Tier 3

Literature Review and Protocol Design Complete

Allows Halucenex to bypass Phase 1 Trial and prepare for Phase 2

Phase 1 Trial

Health Canada approval expected by April 30, 2021

18 participants

Cost: ~C\$20,000 to C\$30,000 per participant

Phase 2 Trial

> 100 participants

Involving:

- an initial screening visit
- a baseline study visit involving psychological and physiological measures related to efficacy and safety
- several therapy visits designed to build rapport between therapist and patient and determine goals for the psilocybin administration session
- a 6 to 8 hour administration visit including psychotherapy
- further psychological and physiological testing.

Cost: ~C\$20,000 to C\$30,000 per participant

Phase 3 Trial Timeframe: 12 months

Phase 3 Trial

July 2020

June 2021

March 2022

March 2023

Long-term strategy



Clinical trials

Clinical trials will focus on the treatment of anxiety and other mental health challenges such as depression and PTSD



Developing IP for a formulation of synthetic psilocybin

Natural psilocybin is less compatible in clinical settings due to inconsistency of potency and therefore dosage, producing synthetic psilocybin in-house will replace third-party supply agreements and potentially allow Halucenex to supply to other distributors and practitioners



Delivery methods

Halucenex plans to develop products across a range of delivery methods such as psilocybin-infused capsules and tinctures



Agile business plan

Fast track to commercialisation via the Veterans market will deliver cash flow early, while maintaining a flexible business plan will allow the company to adapt to the changing regulatory environment

Creso Pharma's Board



Dr Miri Halperin Wernli
Co-Founder & Director

Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries.

She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US. Dr Wernli is currently President of Mind Medicine Inc. (NEO:MMED, OTCQB:MMEDF, DE:MMQ).



MindMed



Boaz Wachtel
Co-Founder & Director

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.

Mr Wachtel was part of the European Coalition for Just and Effective Drug Policies ("ENCOD") which was involved in driving the change in the UN classification of cannabis to a Schedule I substance in December 2020.



Adam Blumenthal
Co-Founder & Non-Executive
Chairman of Creso Pharma

Mr Blumenthal has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries. Using his experience and extensive network of international contacts to provide corporate advisory and capital markets input, he has successfully brought to market several companies and is actively involved in mining, cyber security, agricultural technology, medicinal cannabis, pharmaceutical and information technology sectors.

Mr Blumenthal holds a Bachelor of Commerce, Masters of International Relations and a Masters of Business Administration.



Dr. James Ellingford
Executive Director

Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.

He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

Dr Ellingford holds a Post Graduate in Corporate Management, a Masters in Business Administration as well as a Doctorate in Management. Dr Ellingford also lectures MBA students in Corporate Governance at a leading Sydney University.

Halucenex's Executive Team

Strong track record of commercializing alternative medicines and extensive experience working with Veterans and the Canadian Veterans Affairs Department



William (Bill) Fleming, President & CEO of Halucenex

Mr. Fleming has founded and served as CEO of a number of entrepreneurial companies, and has developed corporate strategies for family-owned businesses to multi-national

companies. He is currently Executive Chairman of Mountain Lake Minerals and was recently President of Mernova Medicinal Inc. which recently sold to Switzerland based Creso Pharma Limited. Mr. Fleming is a Director of SpeakEasy Cannabis. He served as the CFO and Director of NWest Energy Corp.

Mr. Fleming has experience raising equity for small cap companies and has experience in mineral exploration, renewable energy, cannabis and the psychedelic industry.



Major-General (Ret.) David Fraser, Clinical Advisor to Halucenex

Major-General (Retired) David Fraser is one of Canada's most accomplished leaders in both the public and private sectors. He is the President of AEGIS Six Corporation and sits on several boards. David Fraser served for over 31 years with the Canadian Armed Forces. Joining the Second Battalion Princess Patricia Canadian Light Infantry (PPCLI), his career is highlighted by numerous operational tours around the world. He has served in command at every rank from lieutenant to major-general on operations commanding Canadian and multi-national troops.

For his leadership he is one of the most decorated officers Canada has produced. He has been recognized for his leadership by the United States twice (Legion of Merit and Bronze Star), NATO, the Netherlands, Poland, the Atlantic Council and Canadian Defence Academy as a Vimy recipient. He is the recipient of the Commander of Military Merit, the Meritorious Service Cross, and Meritorious Service Medal from Canada.



Don Stewart, Advisor to Halucenex

Dr. Don Stewart is an entrepreneur and scientist with more than 20 years of management experience in the biotechnology industry. He is also the founder and President of Alba Biologics Group. Dr. Stewart served as Director Research of Cangene Corporation from 1997 to 2007. At Cangene, he led programs to develop monoclonal antibodies and recombinant protein drugs; supervised animal efficacy and toxicology studies as well as clinical trial programs; and obtained more than \$15 million in external grant and contract funding over a five-year period.

Dr. Stewart has a PhD in biochemistry from the University of London in the U.K. He has given numerous lectures at international symposia on research management, manufacturing strategies and biosimilar pharmaceuticals.

Appendix 1:

Halucenex and Creso's combined operations will be advised by pioneers in the cannabis and psychedelic industries



Bruce Linton
Strategic Advisor to
Creso Pharma



MindMed

Led Canopy Growth Corporation (TSX:WEED, NYSEWE:CGC) from start-up to US\$15 billion market cap on the NYSE during his six year tenure. Sits as Executive Chair of Gage Cannabis Co., and Director of Mind Medicine Inc. (NEO:MMED, OTCQB:MMEDF, DE:MMQ). Also Co-Chairman and former CEO of tech company Martello Technologies Group Inc. (CVE:MTLO) and Co-Founder of Ruckify Software.



Don Hunter SVP, Halucenex Business Development and Strategic Partnerships

With over 30 years of entrepreneurship and corporate development Don has established an expansive network in the healthcare, bio science, cannabis, and the green tech sectors.

These years of experience has given him the invaluable resources to excel at driving companies to positive revenue, onboarding key partnerships, raising capital, and leading healthcare teams throughout various phases of operations. Don has been instrumental in a number of public offerings amounting to almost a billion dollars in market caps and continues to focus on disruptive intellectual properties, technologies and science that bring good will and well being to the global markets.



David James, Halucenex Qualified Person in Charge (QPIC)

David has a PhD in Chemistry from Memorial University in St. John's Newfoundland and a BSc from Dalhousie University.

David has 7 years in quality assurance, consulting and analytical testing in the cannabis industry. In 2013, he served as the quality assurance person for an up-and-coming licensed producer in Edmonton, Alberta. In 2017, he moved back to the east coast and opened up Nova Scotia's only Health Canada approved Cannabis quality assurance testing laboratory at Perennia Food and Agriculture. He has served as the laboratory director of the lab since its inception.




Jack Yu
Mernova Managing Director

Mr Yu has 25 years of practical experience growing cannabis, including nine years consulting for licensed Canadian medicinal cannabis growers. Mr Yu previously worked for Canopy Growth Corp. (TSX:WEED, NYSE:CGC), the world's largest cannabis company by market cap, as Regional Production Manager for Eastern Canada. Prior to this, he was simultaneously the original Master Grower and Production Manager for MedReleaf Corp., now owned by Aurora Cannabis Inc (TSE:ACB).



Isaac Allen
President Mernova

Mr Allen has significant expertise in optimising business operations from executive positions in industries spanning cannabis, insurance, technology and entertainment. He was formerly National Operations Process Improvement Manager at Canopy, where he developed and executed a number of business strategies and efficiency initiatives. He is also the Founder and former CEO of a disruptive insurance technology startup and has held senior executive positions at various companies.



Mitchel Fleming
Policy and Advocacy

Mitchel Fleming (B.C.L/J.D.) is a law graduate at McGill University. He is currently working at a top Canadian intellectual property law firm and is a published author in the field of gaming law. Fleming is active in the field of legal research and policy focusing on psychedelics in Canada. Fleming has strong strategic relationships in areas of the burgeoning psychedelic industry and the federal government, acting as a conduit through which ideas, policy and business opportunities flow.



Jorge Wernli
Commercial/Market Access Director

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies Novartis, Wyeth, Vifor and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.



Dr. Gian Trepp
Commercial/Marketing Director

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership.

He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.



Dr. Niall Buckley
Alternate QPIC

Canadian Practicing Physician for over 30 years family practice and experience in Veterans PTSD. National University of Ireland, UCC BSc (Hons), MB BCh BAO Human Physiology and Medicine Activities and Societies: College of Physicians and Surgeons of Nova Scotia. College of Family Practice of Canada. Fellowship Anti-Aging Medicine.



Chris Hession
Director of Strategic Partnerships

Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region.

He has held leadership positions with a number of multinational companies and introduced several new ingredients across the APAC region over this time.



Chris Grundy
Chief Financial Officer

Mr Grundy is a career CFO with over 30 years' commercial experience in the life sciences sector, in listed and large multi-national companies as well as early-stage, rapidly-growing businesses. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Young.














Carole Abel
Director of Commercial Operations

Mrs. Carole Abel has over 23 years of experience in multidisciplinary environments, including 15 years in the pharma industry where she has been successfully leading cross-functional teams and directing group such as operations, project management and process improvements.

Appendix 2: Industry leading partners


Partner	Summary
	<ul style="list-style-type: none">• The only Canadian manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications• Psygen will supply Halucenex with synthetic psilocybin from Phase 2 through Phase 4 clinical trials
	<ul style="list-style-type: none">• Health Canada approved provider of integrated drug discovery, development and manufacturing services• Working with Halucenex to test stability and shelf-life testing of psilocybin liquid formulations for use in its Phase 2 clinical trial
	<ul style="list-style-type: none">• Dedicated to cutting edge research that contributes to the development of new treatment options and advancing healthcare• Working with Halucenex on Phase 2 clinical trial
	<ul style="list-style-type: none">• A Canadian not-for-profit organization that has designed and delivered research and training programs in Canada for 20 years• Funding Halucenex's synthetic psilocybin project and botanical extraction projects for novel compounds
	<ul style="list-style-type: none">• University's Centre for Applied Research in Human Health has an in-house NMR (nuclear magnetic resonance) spectrometer• Contracted in a collaborative project to identify compounds for synthetic psilocybin using in-house NMR capability

Appendix 3: Listed global cannabis comparables

	Company	Ticker	Recreational/Medicinal	Market Cap (CAD)
	Canopy Growth Corporation	TSE: WEED	Both	C\$11.82B
	Aurora Cannabis Inc.	TSE: ACB	Both	C\$2.5B
	Curaleaf Holdings Inc.	CNSX: CURA	Both	C\$10.26B
	Green Thumb Industries Inc.	CNSX: GTII	Both	C\$6.7B
	GW Pharmaceuticals plc	NASDAQ: GWPH	Medicinal	C\$6.53B
	Aphria Inc.	TSE: APHA	Both	C\$5.3B
	Cronos Group Inc.	TSE: CRON	Recreational	C\$3.48B
	Tilray Inc.	NASDAQ: TLRY	Both	C\$3.89B
	Trulieve Cannabis Corp.	CNSX: TRUL	Both	C\$5.45B
	Cresco Labs Inc.	CNSX: CL	Both	C\$2.9B
	HEXO Corp.	TSE: HEXO	Both	C\$797M

All Market Cap Values Calculated 1/3/21

Appendix 4: The Creso Group post-acquisition



Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters. This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of the Company. This presentation is not an offer to any person nor is it a prospectus. The Company has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation. This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). To the maximum extent permitted by law, the Company, its related bodies corporate and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including (but not limited to) any liability arising under the Australian Securities and Investments Commission Act 2001, Corporation Act 2001 or from the fault or negligence on the part of any person, for any loss arising from the use of the presentation or its contents arising in connection with it. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.



Thank you

www.halucenex.com

www.cresopharma.com